The methods with the strongest clinical evidence for slowing neurodegenerative disease progression are biomarker-guided anti-amyloid immunotherapies (lecanemab, aducanumab) for early Alzheimer’s disease, riluzole and edaravone for ALS, antisense oligonucleotide (ASO) therapies for genetically defined patients, select neuromodulation approaches, and early, clinic-supervised lifestyle and metabolic programs. None of these reverse disease. What they do, when applied at the right stage with proper monitoring, is measurably reduce the rate of decline on validated clinical and biomarker endpoints. That distinction matters for every decision you make about timing, testing, and care.

The methods covered in this guide:

• Lecanemab (Leqembi) and aducanumab (Aduhelm) — FDA-approved anti-amyloid antibodies for early Alzheimer’s
• Riluzole and edaravone (Radicava) — FDA-approved ALS disease-modifying drugs
• Relyvrio (AMX0035) — a combination ALS therapy (withdrawn from the U.S. market after a confirmatory trial failed to replicate initial results; discussed in context)
• ASO therapies — targeting SOD1 (ALS) and other mutations in genetically defined patients
• Deep brain stimulation (DBS) and repetitive transcranial magnetic stimulation (rTMS) — neuromodulation approaches for Parkinson’s and other conditions
• Ketogenic, MIND, and metabolic dietary programs under clinical supervision
• Multidisciplinary clinic care coordinating all of the above, as offered at Brainrestoremeridian in Meridian, Idaho

Realistic expectation: ClinicalTrials.gov lists hundreds of active trials testing these and next-generation approaches, and the FDA’s approval of lecanemab marked a genuine regulatory milestone. But even the best-performing agents in phase 3 trials slow decline by a fraction of the total trajectory. Earlier intervention, guided by biomarkers, consistently produces better outcomes than waiting for symptoms to become obvious.

Table of Contents

• What does “slowing progression” actually mean clinically?
• How early detection and biomarker testing shape your treatment options
• Which pharmacologic therapies have real evidence for slowing disease progression?
• What ASO and gene therapies can do for genetically defined patients
• Do DBS, rTMS, and focused ultrasound slow the disease or just the symptoms?
• How lifestyle and metabolic programs work as biological interventions
• How clinicians personalize therapy and when you need a specialist
• Safety monitoring, costs, and access realities in the U.S.
• Key Takeaways
• A clinician’s perspective on what actually moves the needle
• Brainrestoremeridian offers a coordinated path forward for patients in Meridian
• Selected authoritative sources and registries for further reading

What does “slowing progression” actually mean clinically?

“Slowing progression” is not the same as symptom relief, and conflating the two leads to real disappointment. A drug that makes you feel better for six months without changing the underlying disease trajectory is symptomatic. A therapy that reduces the rate at which neurons die, plaques accumulate, or function declines is disease-modifying. Regulators and trialists measure these differently, and you should too.

Endpoints used in trials fall into two categories. Clinical endpoints include cognitive scales like the Clinical Dementia Rating Sum of Boxes (CDR-SB), the ALS Functional Rating Scale-Revised (ALSFRS-R), and time to dependency or death. Biomarker endpoints include amyloid PET clearance, cerebrospinal fluid (CSF) phosphorylated tau (p-tau) reduction, and MRI volumetrics tracking brain atrophy rates. The FDA now accepts biomarker endpoints as evidence of disease modification for accelerated approval, which is how aducanumab reached the market and why lecanemab’s full approval was supported by both biomarker and clinical data.

What “slowing” looks like in numbers: In the CLARITY AD trial, lecanemab reduced the rate of clinical decline on the CDR-SB by approximately 27% compared to placebo over 18 months in patients with early Alzheimer’s disease. That is a meaningful signal on a validated scale, but it is not a halt or a reversal.

Three patient-facing implications follow from this:

• Combination strategies are more plausible than single-drug cures. Early, biomarker-guided interventions at multidisciplinary centers improve the chances of meaningful benefit precisely because they coordinate pharmacologic, device-based, and lifestyle approaches rather than relying on any one of them alone.

How early detection and biomarker testing shape your treatment options

The single most consequential decision in managing neurodegenerative disease is when you get tested and which tests you get. Biomarker confirmation is now a prerequisite for most disease-modifying therapies, not an optional add-on.

Who should get which test and when: If you or a family member has early memory symptoms or a family history of Alzheimer’s, plasma p-tau is the most accessible starting point. A positive result should prompt amyloid PET or CSF confirmation before any disease-modifying therapy is considered. For patients with familial ALS or early-onset Parkinson’s disease, genetic testing for SOD1, LRRK2, GBA, and related mutations is a high-value step that can open doors to targeted trials.

Genetic testing for ASO or gene therapy eligibility requires formal genetic counseling, not just a lab order. Counselors help interpret variants of uncertain significance, discuss implications for family members, and connect patients with the specialty centers running mutation-specific trials.

Pro Tip: In a resource-constrained setting, prioritize blood-based biomarkers (plasma p-tau217) first. They are the least invasive and least expensive, and a negative result substantially reduces the probability of AD pathology. Reserve amyloid PET or lumbar puncture for cases where the result will directly change a treatment decision, such as eligibility for an anti-amyloid antibody.

ARIA surveillance deserves specific mention. Patients starting lecanemab or aducanumab require baseline MRI before treatment and repeat MRI at defined intervals during the infusion series, because ARIA (brain swelling or microhemorrhages) can be asymptomatic or clinically significant. APOE ε4 carriers face higher ARIA risk, which affects dosing decisions and monitoring frequency.

Which pharmacologic therapies have real evidence for slowing disease progression?

This is where the evidence is most specific, and where the differences between diseases matter most. The table below summarizes the mandated agents across the comparison dimensions most relevant to clinical decision-making.

Emerging therapeutic reviews consistently highlight that immunotherapies like lecanemab demonstrate slowed decline specifically in selected early Alzheimer’s populations, reinforcing that biomarker confirmation before treatment is not bureaucratic gatekeeping. It is the mechanism by which the therapy actually works.

Practical steps if you are considering these therapies:

• Confirm amyloid status (PET or CSF) before pursuing lecanemab or aducanumab; insurers and Medicare require this documentation.
• Ask your neurologist about APOE genotyping before starting an anti-amyloid antibody, since ε4 homozygotes face substantially higher ARIA risk.
• For ALS, riluzole is typically started at diagnosis; edaravone eligibility depends on disease duration and functional score at baseline.
• Medicare covers lecanemab for beneficiaries enrolled in qualifying registries under Coverage with Evidence Development (CED) requirements. Out-of-pocket costs without coverage can be substantial, so prior authorization documentation from a specialty clinic is worth the effort.

The field is shifting from symptom management toward therapies that target root causes, and personalization by metabolic profile, genetics, and disease stage consistently produces the best outcomes. Brain-penetrant biologics and genotype-guided approaches require clinical oversight and are not one-size-fits-all.

What ASO and gene therapies can do for genetically defined patients

Antisense oligonucleotides are short synthetic strands of nucleic acid that bind to a target messenger RNA and reduce production of a harmful protein. For patients with a confirmed pathogenic mutation, this approach can be far more precise than any broad-spectrum drug.

The clearest current example is tofersen (Qalsody), an ASO targeting SOD1 in ALS patients with SOD1 mutations. The FDA granted accelerated approval in 2023 based on its ability to reduce SOD1 protein levels in CSF, with ongoing confirmatory trials assessing functional outcomes. For LRRK2-associated Parkinson’s disease, multiple ASO and small-molecule LRRK2 inhibitor programs are in phase 2 trials. Genetic stratification materially changes trial access and therapeutic options: mutation carriers qualify for targeted trials with clearer signals of efficacy than non-stratified approaches.

Gene therapy programs, which aim to deliver corrective genetic material directly to neurons, remain largely in early-phase trials for most neurodegenerative diseases. Delivery across the blood-brain barrier is the central technical hurdle, and most programs use intrathecal or direct CNS injection routes to bypass it.

Common eligibility criteria for ASO and gene therapy trials:

• Confirmed pathogenic mutation (SOD1, LRRK2, GBA, HTT, or others depending on the program)
• Early disease stage (most trials exclude patients with advanced functional loss)
• Adequate organ function (liver, kidney, cardiac) for drug metabolism and monitoring
• No contraindications to intrathecal or IV delivery
• Willingness to attend a specialty center for infusions and follow-up visits

Finding the right trial starts at ClinicalTrials.gov, where you can filter by disease, intervention type (gene therapy, ASO), and recruiting status. University-based ALS centers, Parkinson’s disease research consortia, and Huntington’s disease specialty programs maintain their own trial pipelines and often have coordinators who can expedite screening.

Pro Tip: Get genetic testing and counseling before you need it, not after a trial opens. Genotype stratification is now a prerequisite for the most targeted and potentially effective trials. Patients who arrive at a specialty center with confirmed mutation status and a recent functional assessment move through screening far faster than those who need to complete that workup from scratch.

Do DBS, rTMS, and focused ultrasound slow the disease or just the symptoms?

This is the most important question to ask before committing to any neuromodulation procedure, and the honest answer varies by modality and disease.

Deep brain stimulation (DBS) delivers continuous electrical pulses to specific brain targets (most commonly the subthalamic nucleus or globus pallidus interna in Parkinson’s disease). It is one of the most effective symptomatic treatments available for motor fluctuations and dyskinesia in PD. Evidence for disease modification, meaning a change in the underlying rate of neurodegeneration, is not established. DBS is a surgical procedure with real risks: hardware complications, infection, and the need for ongoing device management.

Repetitive transcranial magnetic stimulation (rTMS) uses magnetic pulses delivered through the scalp to modulate cortical excitability. It has FDA clearance for depression and is being studied for cognitive symptoms in Alzheimer’s disease and motor symptoms in PD. Current evidence supports symptomatic benefit in select patients; disease-modifying effects have not been demonstrated in large RCTs. Neurofeedback and neuromodulation approaches at outpatient clinics like Brainrestoremeridian can complement these approaches as part of a broader rehabilitation plan.

Focused ultrasound (FUS) can ablate specific brain targets without surgery and has FDA clearance for essential tremor and PD tremor. Like DBS, its primary role is symptomatic.

Symptomatic vs. disease-modifying evidence by modality:

• DBS: Strong symptomatic evidence for PD motor symptoms; no established disease-modifying effect
• rTMS: Moderate symptomatic evidence for depression; early-stage evidence for cognitive and motor symptoms in AD and PD; no confirmed disease modification
• Focused ultrasound: Strong symptomatic evidence for tremor; no established disease-modifying effect
• Neurofeedback: Emerging evidence for cognitive rehabilitation support; used as an adjunct in multidisciplinary programs

Eligibility checklist before pursuing DBS or focused ultrasound:

1. Neurosurgical evaluation confirming appropriate brain target and anatomy
2. Neuropsychological assessment (cognitive status affects surgical candidacy)
3. Cardiac and general medical clearance
4. Realistic goals discussion with the surgical team (symptom relief, not disease reversal)
5. Caregiver support plan for the perioperative period

When asking a specialist about neuromodulation, the most useful questions are: What specific symptom or functional outcome will this address? What is the expected duration of benefit? What monitoring and programming visits will be required? And is there any evidence this changes the underlying disease course?

How lifestyle and metabolic programs work as biological interventions

Lifestyle measures are not a consolation prize when drugs are unavailable. They are biological modulators with documented effects on the mechanisms that drive neurodegeneration, and they work best when prescribed and monitored in a clinical setting rather than self-administered.

The mechanistic case is solid. Exercise increases brain-derived neurotrophic factor (BDNF), reduces neuroinflammation, and enhances autophagy, the cellular process that clears misfolded proteins. Dietary strategies that induce metabolic switching, such as ketogenic or intermittent fasting protocols, activate SIRT1, AMPK, and mTOR pathways that regulate protein aggregation and mitochondrial health. Review evidence shows that exercise and dietary strategies improve BDNF, autophagy, and reduce pathological protein burden, and multimodal lifestyle approaches appear to produce greater benefit than any single intervention.

Clinic-administered interventions that have clinical support:

• Ketogenic and MIND dietary protocols under medical supervision: ketogenic interventions affect mitochondrial function, oxidative stress, and protein aggregation pathways, though long-term adherence and clinical efficacy data remain mixed

A multidisciplinary clinic workflow typically begins with intake testing that includes metabolic profiling, functional assessment, and relevant biomarker or genetic testing. From there, a personalized plan is built that may combine pharmacologic management with neurofeedback, photobiomodulation, supervised rehabilitation, and regular re-evaluation. Functional medicine approaches that address root-cause metabolic and inflammatory drivers are a natural fit within this model.

Pro Tip: For patients with motor-predominant conditions like ALS, prioritize resistance training early, before significant muscle mass is lost. For Alzheimer’s and other amnestic presentations, aerobic exercise has the strongest cognitive evidence and should anchor the physical activity prescription. The two are not interchangeable.

How clinicians personalize therapy and when you need a specialist

No two patients with Alzheimer’s, Parkinson’s, or ALS have exactly the same disease. Personalization is not a marketing phrase. It is the practical reality that the right therapy at the wrong stage, or for the wrong genotype, produces little benefit and real risk.

The key axes that drive therapy selection:

1. Disease type and stage: Anti-amyloid antibodies are only appropriate for early AD with confirmed amyloid pathology. Riluzole is started at ALS diagnosis. DBS is considered after adequate medication trials in PD.
2. Biomarker and genotype: Amyloid PET or CSF confirmation for AD therapies; SOD1 or LRRK2 status for targeted ASO/gene therapy access; APOE ε4 status for ARIA risk stratification.
3. Comorbidities: Cardiovascular disease, diabetes, sleep apnea, and depression all affect both disease trajectory and therapy tolerability.
4. Patient goals and logistics: Some patients prioritize functional independence; others prioritize trial access. Infusion-based therapies require reliable transportation and caregiver support.

Referral checklist: what to do before seeing a specialist

1. Obtain a recent neuropsychological evaluation or functional assessment (within 6 months)
2. Compile prior MRI or imaging reports
3. Request relevant blood work (metabolic panel, thyroid, B12, inflammatory markers)
4. Ask your primary care physician for a referral to a neurologist or memory/movement disorder specialist
5. Bring a list of all current medications and supplements
6. Prepare questions about biomarker testing, trial eligibility, and monitoring requirements

Questions worth asking at a specialist visit: What is the expected magnitude of benefit from the recommended therapy? What does the monitoring schedule look like for the first year? How does this therapy interact with my current medications? Is there a clinical trial I should consider given my stage and genotype? What happens if the therapy is not working at the next assessment?

The multidisciplinary clinic model adds value precisely because it coordinates these questions across disciplines. A neurologist, functional medicine clinician, rehabilitation specialist, and care coordinator working from the same patient record can move faster, catch interactions earlier, and connect patients to trials more efficiently than fragmented specialist visits. Integrated strategies for cognitive decline are most effective when the team communicates in real time rather than through referral letters.

Safety monitoring, costs, and access realities in the U.S.

Understanding the safety and financial landscape before starting a disease-modifying therapy prevents surprises that derail treatment.

Monitoring requirements by therapy:

• Lecanemab / aducanumab: Baseline MRI before first infusion; repeat MRI at weeks 26 and 52 (minimum); more frequent imaging for APOE ε4 carriers or if ARIA is detected; clinical reassessment at each infusion visit
• Riluzole: Liver function tests at baseline, monthly for 3 months, then quarterly; complete blood count monitoring
• Edaravone: Infusion site monitoring; complete blood count; renal function if oral form is used
• DBS: Device programming visits every 3–6 months; battery replacement surgery every 3–5 years depending on device; infection surveillance
• rTMS: Session-by-session tolerability assessment; no laboratory monitoring required

ARIA deserves specific attention. It occurs in a meaningful proportion of patients on anti-amyloid antibodies, more commonly in APOE ε4 carriers. Most ARIA episodes are asymptomatic and detected only on surveillance MRI, but symptomatic ARIA (headache, confusion, vision changes) requires immediate imaging and may necessitate treatment interruption. Patients and caregivers should know the warning signs before the first infusion.

Integrating palliative care principles alongside disease-modifying efforts is not a sign of giving up. It is a recognition that quality of life, symptom management, and goals-of-care planning are parallel priorities, not sequential ones. The earlier these conversations happen, the better the care plan reflects what actually matters to the patient.

Insurance and cost considerations:

• Medicare covers lecanemab under Coverage with Evidence Development (CED) for beneficiaries enrolled in qualifying registries; prior authorization requires documented amyloid confirmation and clinical criteria
• Riluzole and edaravone are covered by most Medicare Part D plans and commercial insurers, though step therapy and prior authorization requirements vary
• Patient assistance programs from manufacturers (Eisai for lecanemab, Mitsubishi Tanabe for edaravone) can reduce out-of-pocket costs for eligible patients
• Clinical trial participation typically covers the cost of the investigational drug and protocol-required testing; standard-of-care costs may still fall to insurance

Pro Tip: Ask your clinic to prepare a detailed prior authorization letter that includes the biomarker confirmation result, the clinical indication, and the relevant FDA label language. Denials are more common when documentation is incomplete. A clinic experienced with these therapies will have templates that significantly improve first-pass approval rates.

Neurological rehabilitation services are often separately billable and covered under Medicare Part B when medically necessary, which means the rehabilitation component of a multidisciplinary program may be more accessible than patients expect.

Key Takeaways

The most effective approach to slowing neurodegenerative disease progression combines biomarker-guided pharmacologic therapy, targeted genetic or ASO treatment where applicable, supervised lifestyle and metabolic programs, and coordinated multidisciplinary monitoring starting as early as possible.

A clinician’s perspective on what actually moves the needle

The conventional framing of neurodegenerative disease care still tends to present pharmacology and lifestyle as separate tracks, with drugs doing the real work and lifestyle as something patients do on their own between appointments. That framing is wrong, and it costs patients real benefit.

What the evidence actually shows is that the patients who do best are the ones who arrive early, with biomarker confirmation in hand, and who are enrolled in a program that treats exercise, metabolic health, sleep, and cognitive engagement as prescribed interventions with the same seriousness as an infusion schedule. The mechanistic rationale for this is not speculative. BDNF upregulation from aerobic exercise, autophagy enhancement from metabolic switching, and glymphatic clearance during optimized sleep are documented biological effects that operate on the same pathways that drugs target. Modern multidisciplinary neurorestorative programs that combine personalized diet, physical activity, and neuromodulation represent the current standard for coordinated care, not a fringe approach.

The patients who benefit most from early multidisciplinary care tend to share a few characteristics: they are in early or mild disease stages, they have at least one confirmed biomarker or genetic finding that guides therapy selection, and they have a caregiver or support person who can help with logistics and monitoring. A patient who comes in with a recent MRI, a plasma p-tau result, and a clear functional baseline can move from evaluation to a personalized care plan in a single intake visit. That speed matters, because the window for meaningful intervention is not indefinite.

Coordinating referrals to specialty neurology, facilitating trial screening, and managing the documentation burden for insurance prior authorization are not incidental services. They are often the difference between a patient accessing lecanemab or a targeted ASO trial and a patient who was eligible but never got there. The clinic’s role is to hold the map and help you move through it efficiently.

Brainrestoremeridian offers a coordinated path forward for patients in Meridian

If you have read this far, you already understand that slowing neurodegenerative disease progression is not a single-drug problem. It requires the right tests, the right timing, and a care team that can coordinate pharmacologic, device-based, and lifestyle strategies without dropping the thread between specialist visits.

Brainrestoremeridian, located in Meridian, Idaho, is built around exactly that model. The clinic offers neurofeedback for neurodegenerative patients, photobiomodulation and laser therapy, metabolic profiling, supervised rehabilitation, and neurodiagnostic testing including qEEG brain mapping. These services are not offered in isolation. They are coordinated within a personalized care plan that accounts for your disease stage, biomarker status, comorbidities, and goals.

The clinic also helps patients navigate the practical barriers that stop many people from accessing the therapies described in this guide: prior authorization documentation, specialist referral coordination, and trial screening preparation. If you are in the Treasure Valley area and want a clear picture of where you stand and what options are available to you, the right next step is to schedule a comprehensive evaluation at Brainrestoremeridian. You can reach the clinic directly through brainrestoremeridian.com to request an appointment or ask about the intake process.

This article provides general health information and is not a substitute for professional medical advice. Please consult a qualified neurologist or healthcare provider to confirm current treatment options and guidelines for your specific situation.

Selected authoritative sources and registries for further reading

The sources below are the primary references used in this article and the most useful registries for patients and caregivers seeking additional detail.

• Modern Methods of Diagnostics and Treatment of Neurodegenerative Diseases and Depression — PMC
• Emerging Breakthroughs in Neurodegenerative Disease Treatments: Kavita Nair, PhD, FAAN
• medlineplus.gov
• clinicaltrials.gov

Recommended

• How Functional Medicine Slows Neurodegeneration
• How Neurofeedback Supports Neurodegenerative Patients
• Brain Health: Integrated Strategies from Align Clinic
• Cognitive Decline Treatment in Meridian: 2026 Guide